IL245977A0 - Combinations of gabapentinoids and sigma receptors - Google Patents

Combinations of gabapentinoids and sigma receptors

Info

Publication number
IL245977A0
IL245977A0 IL245977A IL24597716A IL245977A0 IL 245977 A0 IL245977 A0 IL 245977A0 IL 245977 A IL245977 A IL 245977A IL 24597716 A IL24597716 A IL 24597716A IL 245977 A0 IL245977 A0 IL 245977A0
Authority
IL
Israel
Prior art keywords
gabapentinoids
receptor ligands
sigma receptor
combinations
ligands combinations
Prior art date
Application number
IL245977A
Other languages
English (en)
Hebrew (he)
Inventor
Daniel Zamanillo-Castanedo
Enrique Portillo-Salido
Original Assignee
Esteve Labor Dr
Daniel Zamanillo-Castanedo
Enrique Portillo-Salido
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49876521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL245977(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esteve Labor Dr, Daniel Zamanillo-Castanedo, Enrique Portillo-Salido filed Critical Esteve Labor Dr
Publication of IL245977A0 publication Critical patent/IL245977A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL245977A 2013-12-17 2016-06-01 Combinations of gabapentinoids and sigma receptors IL245977A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382517 2013-12-17
PCT/EP2014/077992 WO2015091505A1 (en) 2013-12-17 2014-12-16 Gabapentinoids and sigma receptor ligands combinations

Publications (1)

Publication Number Publication Date
IL245977A0 true IL245977A0 (en) 2016-07-31

Family

ID=49876521

Family Applications (1)

Application Number Title Priority Date Filing Date
IL245977A IL245977A0 (en) 2013-12-17 2016-06-01 Combinations of gabapentinoids and sigma receptors

Country Status (16)

Country Link
US (1) US20160310501A1 (enExample)
EP (1) EP3082790A1 (enExample)
JP (1) JP2017503765A (enExample)
KR (1) KR20160098426A (enExample)
CN (1) CN105873580B (enExample)
AR (1) AR101637A1 (enExample)
AU (1) AU2014364644A1 (enExample)
CA (1) CA2933057A1 (enExample)
IL (1) IL245977A0 (enExample)
MA (1) MA39146A1 (enExample)
MX (1) MX2016007286A (enExample)
PH (1) PH12016501095A1 (enExample)
SG (1) SG11201604478UA (enExample)
TN (1) TN2016000229A1 (enExample)
TW (1) TW201607539A (enExample)
WO (1) WO2015091505A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
SG11201604480PA (en) 2013-12-17 2016-07-28 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
CA3085939A1 (en) * 2017-12-19 2019-06-27 University Of Tennessee Research Foundation W/o/w microemulsions for ocular administration
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN120437109B (zh) * 2025-07-09 2025-09-26 湖南一格制药有限公司 一种稳定性优异的苯磺酸美洛加巴林制剂组合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1992009560A1 (en) 1990-11-27 1992-06-11 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
DK0641330T3 (da) 1992-05-20 2001-12-03 Univ Northwestern Gaba- og L-glutaminsyreanaloger til antikrampeanfaldsbehandling
ATE323067T1 (de) 1997-10-27 2006-04-15 Warner Lambert Co Zyklische aminosäuren und deren derivate als arzneimittel
WO1999031074A2 (en) 1997-12-16 1999-06-24 Warner-Lambert Company ((cyclo)alkyl substituted)-.gamma.-aminobutyric acid derivatives (=gaba analogues), their preparation and their use in the treatment of neurological disorders
CN1279667A (zh) 1997-12-16 2001-01-10 沃尼尔·朗伯公司 4(3)取代－4(3)－氨基甲基－(硫代)吡喃(噻喃)或－哌啶衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
NZ503963A (en) 1997-12-16 2002-09-27 Warner Lambert Co 1-substituted-1-aminomethyl-cycloalkane derivatives, or gabapentin analogues, preparation and use in the treatment of neurological disorders
JP2002516312A (ja) 1998-05-26 2002-06-04 ワーナー−ランバート・カンパニー カルシウムチャンネルのα２δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物
US6166072A (en) 1998-08-03 2000-12-26 Allelix Neuroscience, Inc. Amino acid derivatives
WO2000031020A1 (en) 1998-11-25 2000-06-02 Warner-Lambert Company Improved gamma amino butyric acid analogs
US6451857B1 (en) * 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
JP2003500466A (ja) 1999-05-26 2003-01-07 ワーナー−ランバート・カンパニー 医薬としての融合多環式アミノ酸
PT1185524E (pt) 1999-05-28 2005-04-29 Warner Lambert Co Analogos de gaba substituidos por 3-heteroarilalquilo
JP2003525207A (ja) 1999-06-02 2003-08-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 薬剤として有用なアミノ複素環
CA2444053C (en) 2001-04-19 2008-06-17 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
KR101352012B1 (ko) * 2004-08-27 2014-01-15 라보라토리오스 델 드라. 에스테브.에스.에이. 시그마 수용체 저해제
EP1820502A1 (en) * 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2292236A1 (en) 2009-08-14 2011-03-09 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention or treatment of pain induced by chemotherapy
EP2335688A1 (en) 2009-11-25 2011-06-22 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions comprising sigma receptor ligands
DK2503993T3 (en) 2009-11-25 2016-08-22 Esteve Labor Dr Hydrochloridsalt af 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]-morpholin
EP2353591A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
MA34047B1 (fr) 2010-02-04 2013-03-05 Esteve Labor Dr Polymorphes et solvates de chlorhydrate de 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) * 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2460519A1 (en) 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2818166A1 (en) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)

Also Published As

Publication number Publication date
WO2015091505A1 (en) 2015-06-25
KR20160098426A (ko) 2016-08-18
AU2014364644A1 (en) 2016-06-23
EP3082790A1 (en) 2016-10-26
JP2017503765A (ja) 2017-02-02
CA2933057A1 (en) 2015-06-25
MA39146A1 (fr) 2017-11-30
PH12016501095A1 (en) 2016-07-11
CN105873580B (zh) 2020-08-25
CN105873580A (zh) 2016-08-17
AR101637A1 (es) 2017-01-04
SG11201604478UA (en) 2016-07-28
TW201607539A (zh) 2016-03-01
US20160310501A1 (en) 2016-10-27
MX2016007286A (es) 2016-08-04
TN2016000229A1 (en) 2017-10-06

Similar Documents

Publication Publication Date Title
EP2958596A4 (en) PSMA LIGANDS AND USE THEREOF
SG11201508538SA (en) Complex
GB2516895C (en) Structured particles
SG11201601304XA (en) Nsaid and sigma receptor ligand combinations
SG11201604478UA (en) Gabapentinoids and sigma receptor ligands combinations
SG11201508102XA (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
PL3470074T3 (pl) Probiotyki
IL242777A (en) Building system elements
ZA201601880B (en) Hetero-transglycosylase and uses thereof
GB201320992D0 (en) Complex and uses thereof
GB201322919D0 (en) Brake arrangement
GB201309180D0 (en) Compounds and Their Uses
GB201314610D0 (en) Compounds and their uses
GB201306248D0 (en) Compounds and their uses
TWM475375U (en) Armrest
GB201516703D0 (en) Digital verification
GB201311696D0 (en) Assembly and methods
HK1230089A1 (en) Gabapentinoids and sigma receptor ligands combinations
GB201310268D0 (en) Seating
GB201309248D0 (en) Compounds and combinations
GB201311534D0 (en) Concept fifteen
HK1224933A1 (en) Nsaid and sigma receptor ligand combinations
GB201301393D0 (en) Kiddibidet and pottibidet
GB201302364D0 (en) Seats
GB201317353D0 (en) Ed